Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. group

Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news